GHB is the active component of the sodium oxybate (Xyrem) prescription drug. GHB was used for general anesthesia and cataplexy, narcolepsy, and alcoholism in a medical environment. In changed sleep latency experiments, GHB increased slow-wave sleep reliably and decrease its propensity for REM sleep.
Gamma-Hydroxybutyric acid (GHB), also known as 4-hydroxybutyric acid, is a naturally occurring neurotransmitter and psychotropic medical medication. Some regions of the brain include precursors of GABA, glutamate, and glycine. On both the GHB and GABAB receptors, this is a moderate agonist. In a medical setting, GHB was used for general anesthesia, cataplexy, narcolepsy, and alcoholism. This substance is also illegally used for overdosing, fitness enhancement, date rape, and recreational purposes. It’s also used illegally as an athletic replacement.
In sodium -hydroxybutyrate (NaGHB, sodium oxybate, or Xyrem) or potassium -hydroxybutyrate, GHB can be found in small levels in some beer and wines, meat, and small citrus fruits (KGGHB, potassium oxybate).
The most prevalent health uses for GHB nowadays are narcoleptic treatment and, less commonly, alcoholism, but its utility for alcoholism has not been proven by randomized controlled studies. For fibromyalgia diagnosis, off-label treatments are occasionally utilized. GHB is the active ingredient in the prescription medication sodium oxybate (Xyrem). Sodium oxybate has received approval in the United States. Cataplexy is treated with narcotics and EDS (extended daily drowsiness), both of which are linked with narcolepsy. GHB was found to reliably promote slow-wave sleep and reduce its tendency for REM sleep in altered sleep latency tests. GHB is a central nervous system depressant that is used as a medication.